Last reviewed · How we verify
PTV/r/OBV/DSV
This is a fixed-dose combination of hepatitis C virus (HCV) protease and NS5A inhibitors that blocks viral replication by inhibiting essential nonstructural proteins.
This is a fixed-dose combination of hepatitis C virus (HCV) protease and NS5A inhibitors that blocks viral replication by inhibiting essential nonstructural proteins. Used for Chronic hepatitis C virus infection (genotype 1).
At a glance
| Generic name | PTV/r/OBV/DSV |
|---|---|
| Also known as | Viekirax/Exviera |
| Sponsor | National Taiwan University Hospital |
| Drug class | HCV direct-acting antiviral combination |
| Target | HCV NS3/4A protease, NS5A, NS5B polymerase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
PTV/r/OBV/DSV combines paritaprevir (protease inhibitor), ritonavir (booster), ombitasvir (NS5A inhibitor), and dasabuvir (NS5B inhibitor) to target multiple steps of the HCV replication cycle. The combination achieves high cure rates across multiple HCV genotypes by preventing viral protein synthesis and RNA replication.
Approved indications
- Chronic hepatitis C virus infection (genotype 1)
Common side effects
- Fatigue
- Headache
- Nausea
- Pruritus
- Elevated bilirubin
Key clinical trials
- MHH-HCV-NPM-Neuropsychiatric Manifestations of HCV-infection During and After Treatment With OBV/PTV/r and DSV (PHASE4)
- Proof of Concept Study To Evaluate the Efficacy and Justification Of OBV/PTV/r and DSV In Adults With Chronic Hepatitis C Virus Genotype 2K/1B (PHASE4)
- PrOD for Non-Cirrhotic Patients With HCV-1b Receiving Hemodialysis (PHASE4)
- A Study to Investigate HCV Response Rates in Real World Patients: HEARTLAND Study (PHASE4)
- A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/r With or Without Dasabuvir and With or Without Ribavirin in Chronic Hepatitis C Virus Genotype 1 or 4 Infected Adults With Successfully Treated Early Stage Hepatocellular Carcinoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PTV/r/OBV/DSV CI brief — competitive landscape report
- PTV/r/OBV/DSV updates RSS · CI watch RSS
- National Taiwan University Hospital portfolio CI